by icia icia

Pharmacogenomic impact of the determination of VKORC1 and CYP2C9 genes over the efficacy, safety and costs of the anticoagulant treatment, TROMBOGEN

Objectives:
to investigate the pharmacogenomic status of the patients, from both geno- andphenotypic point of view;
to reveal the polymorphism of the CYP2C9 and VKORC1 genes, and alsoof the genes involved in the thrombophilia phenomenon (Factor V Leiden, FII G20210A, PAI-1 4G/5G, MTHFR C677T and A1298C) and the possible relationship between the presence of these polymorphisms and the response to acenocumarol treatment;

Read more